New updates have been reported about PsyLabs.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
PsyLabs has exercised a put option that compels Psyence BioMed to invest US$5 million in the psychedelic API manufacturer via a share-for-share exchange, solidifying PsyLabs’ role as the group’s core production and supply platform. In return, PsyLabs will issue 2,900 of its own shares at a US$1,724-per-share valuation, while receiving 1,146,159 Psyence BioMed common shares valued off a 30-day VWAP of US$4.36, with closing targeted around February 25, 2026 and no cash changing hands.
Following completion, PsyLabs is expected to beneficially own roughly 49.98% of Psyence BioMed’s outstanding equity, materially increasing its governance influence and tightening strategic alignment around long-term access to pharmaceutical-grade psychedelic manufacturing capacity. The transaction remains subject to customary conditions, including confirmation that no material adverse events have affected PsyLabs, and was reviewed by an independent special committee of Psyence BioMed’s board that evaluated the commercial rationale and a third-party valuation of PsyLabs’ business, which includes regulated cultivation, extraction, and export of psilocybin, ibogaine, and other psychedelic compounds into key medical and research markets.